Scanlan Sean F. 4

What Happened
Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, exercised stock options (transaction code M) on February 10, 2026 to acquire 16,875 shares at $1.05 per share, for a cash outlay of $17,719. The filing also shows a simultaneous disposition entry for 16,875 shares listed as a derivative conversion (reported at $0.00), consistent with the conversion/termination of the option instrument upon exercise. This was an option exercise (acquisition), not a sale of shares on the open market.

Key Details

• Transaction date: 2026-02-10 (Form filed 2026-02-11 — timely filing)
• Exercise: 16,875 shares acquired @ $1.05 / share = $17,719 total
• Disposition entry: 16,875 shares reported as disposed at $0.00 (derivative conversion associated with the exercise)
• Shares owned after transaction: Not specified in the supplied excerpt of the filing
• Footnotes:
  • F1: Includes 511,291 restricted stock units in reported holdings.
  • F2: The option vested in equal annual installments over 4 years starting Jan 30, 2017, with final vesting Jan 30, 2021.
• No 10b5‑1 plan, tax‑withholding sale, or immediate open‑market sale is indicated in the provided data.

Context
This was an options exercise (code M). The paired “disposed” line at $0.00 typically reflects termination/conversion of the derivative instrument on exercise rather than an outright sale of shares for cash. Because this is an acquisition via exercise (not a sale), it’s generally viewed as a neutral-to-bullish insider action in terms of alignment with the company, but filings don’t disclose the insider’s motive.